the perpetuation of fibroblast activation and fibrogenesis in the kidney, leading to glomerular and interstitial fibrosis (9) .
Among epigenetic regulation, global histone acetylation alters chromatin structure and 70 regulates the dynamics of gene expression. The level of acetylation reflects a balance between histone acetyltransferase (HAT) and histone deacetylase (HDAC) protein families (10) . Recently, it was demonstrated that HDACs are related to the progression of tissue fibrosis in multiple organs including kidney, heart and lung (11). A report showed that HDAC levels were increased and histone acetylation was decreased in kidneys injured by 75 unilateral ureteral obstruction (UUO), which is a model of fibrosis (12) . In addition, it has been reported that HDAC inhibitors (HDACi) are potentially therapeutic for fibrotic disorders because they have anti-fibrotic activity. Among HDACi, suberoylanilide hydroxamic acid (SAHA) has nonspecific HDAC-inhibition activity, affecting all classes of HDACs, and has received approval from the US Food and Drug Administration for treatment 80 of refractory cutaneous T-cell lymphoma (13). SAHA exhibits relatively low toxicity towards normal cells compared to other HDACi (13). It was reported that SAHA attenuated mesangial collagen IV deposition in a mouse model of diabetic nephropathy (14) . In addition, SAHA also attenuated collagen deposition in the ventricle and cell infiltration throughout the interstitium; thereby, improving cardiovascular remodeling in deoxycorticosterone acetate- 85 salt hypertensive rats (15) . Furthermore, previous reports indicate that inflammation plays an important role in the progression of organ fibrosis, and angiogenesis is associated with the development of fibrosis (16, 17) . It has been also reported that SAHA suppressed inflammation and angiogenesis (18, 19) . Therefore, we used SAHA as an HDACi in our present study. 90 Io K, et al., Page 5 Generally, increased levels of histone acetylation are associated with transcriptional activation (20) . Some reports indicate that the expression of fibrosis inhibitory factors can be increased by promoting histone acetylation (21, 22) . As the effects of inhibitory factors for fibrosis, Yu et al. reported that bone morphogenetic protein 7 (BMP-7) and hepatocyte growth factor (HGF) ameliorated high-glucose-induced epithelial-to-mesenchymal transition 95 (EMT) of peritoneal mesothelial cells (23) . Inhibitors of DNA binding/differentiation 2 (Id2), which plays a role in inhibiting TGF-xxb-induced EMT in human renal epithelial cells, were shown to be upregulated, together with BMP-7, by HDACi (21) .
In the present study, we hypothesized that HDACi could inhibit peritoneal fibrosis by promoting histone acetylation, following the increase of a fibrosis inhibitory factor; we 100 focused on BMP-7. In this study, we investigated first the changes in histone acetylation in the CG-induced fibrotic peritoneum of mice. Then, we determined the effects of HDACi on fibrotic changes induced by CG.
Our results raise the possibility that HDACi may be a useful therapeutic agent for attenuating the progression of peritoneal fibrosis. 105 Io K, et al., Page 6 
METHODS

ANIMAL MODELS
The experiments described in this study were conducted on 10-week-old male ICR mice (Japan SLC Inc., Shizuoka, Japan). They were housed in standard rodent cages in a light-and 110 temperature-controlled room in the Biomedical Research Center, Center for Frontier Life Sciences, Nagasaki University. They had free access to laboratory food and tap water. The experimental protocol was inspected by the Animal Care and Use Committee of Nagasaki University, and approved by the President of Nagasaki University (Approval number: 1004050846). 115 
EXPERIMENTAL PROTOCOL
Peritoneal fibrosis was induced by intraperitoneal injection of 0.1% CG in 15% ethanol dissolved in saline, as described previously, but with a slight modification (16, 24) . Mice received injections of 0.1% CG in 15% ethanol dissolved in saline (CG) or 15% ethanol dissolved in saline only at a dose of 0.3 mL/body into the peritoneal cavity every other day 120 for 3 weeks. SAHA (10009929; Cayman Chemicals, MI, USA), which was dissolved in a vehicle (dimethylsulfoxide:saline = 1:1), or a vehicle alone, was administered subcutaneously, as previously reported (25) . SAHA was administered at a dose of 25 mg/kg body weight every day for 3 weeks. Mice were assigned to 4 groups: (1) mice injected 15% ethanol dissolved in saline intraperitoneally and vehicle subcutaneously (n = 5), defined as the 125 control group; (2) mice injected 15% ethanol dissolved in saline intraperitoneally and SAHA subcutaneously (n = 5), defined as SAHA group; (3) mice injected CG intraperitoneally and vehicle subcutaneously (n = 10), defined as CG group; and (4) mice injected CG intraperitoneally and SAHA subcutaneously, defined as CG + SAHA group (n = 10). The Io K, et al., Page 7 dose and interval for administration of SAHA were selected on the basis of pilot studies 130 conducted to determine the effects of different doses on the thickness of the submesothelial area. SAHA at a dose of 12.5 mg/kg body weight did not reduce peritoneal thickness compared with that in non-treated CG mice. SAHA at doses of 25 or 50 mg/kg body weight reduced peritoneal thickness to the same degree. Therefore, we selected 25 mg/kg body weight in the present study. No mice were excluded from the study once they were treated. 135 Mice were sacrificed at day 21 after the first CG injection, and peritoneal tissues were dissected out carefully. To avoid direct damage to the peritoneum due to repeated injections, CG was injected at the lower part of the peritoneum, whereas the upper portion of the parietal peritoneum was used for the examination. The tissues were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS; pH 7.4) immediately after sampling, and were embedded 140 in paraffin. For morphological examination of the peritoneum, 4-xxmm thick, paraffinembedded tissues were stained with Masson's trichrome staining.
IMMUNOHISTOCHEMISTRY
Paraffin-embedded tissue sections were stained immunohistochemically using an indirect method (26). The following antibodies were used for immunohistochemistry: (1) rabbit anti-145 type III collagen antibody diluted 1:400 (LB-1393; LSL Co., Tokyo, Japan); (2) rabbit antihuman phosphorylated-Smad2/3 antibody diluted 1:50 (sc-11769-R; Santa Cruz Biotechnology, Santa Cruz, CA, USA); (3) rabbit anti-human fibroblast-specific protein-1 (FSP-1) antibody diluted 1:100 (A5114; DAKO, Glostrup, Denmark); (4) mouse anti-human xxaSMA antibody diluted 1:50 (A2547; Sigma-Aldrich, St.Louis, US); (5) rat anti-mouse 150 F4/80 antibody diluted 1:50 (MCA 497; Serotec, Kidlington, UK); and (6) goat anti-mouse PECAM/CD31 antibody diluted 1:50 (sc-1506; Santa Cruz Biotechnology). Io K, et al., Page 8 After deparaffinization, the sections were treated with 0.3% H2O2 for 20 min to inactivate endogenous peroxidase activity. For the immunohistochemical analysis of phosphorylated-Smad2/3 and CD31, the sections were treated in a microwave oven (MI-77; Azumaya, Tokyo, 155 Japan) at 95°C for 5 or 15 min in 10 mmol/L citrate buffer (pH 6.0), before H2O2 treatment for antigen retrieval. For the immunohistochemical analysis of type III collagen, FSP-1, F4/80 and xxaSMA, the sections were treated with proteinase K (P2308; Sigma, St Louis, MO) for 15 min at 37°C, before H2O2 treatment for antigen retrieval. The sections were incubated for 30 min with a blocking solution (5% normal goat serum, 5% fetal calf serum, 160 5% bovine serum albumin (BSA), and 20% normal swine serum in PBS) at room temperature.
The sections were then exposed to the primary antibody, which was diluted in the blocking buffer. For phosphorylated-Smad2/3 and CD31 staining, the sections were stained with the avidin-biotin complex by using a Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) after reacting with the primary antibody overnight at 4°C. For xxaSMA, the 165 sections were exposed to a complex of anti-xxaSMA antibody and horseradish peroxidase (HRP)-conjugated rabbit anti-mouse immunoglobulin antibody (P0161; Dako) diluted 1:50 for 30 min at room temperature. Then, sections were incubated with the Envision + System-HRP Labelled Polymer Anti-Rabbit (K4002, Dako) for 30 min at room temperature. For type III collagen, FSP-1 and F4/80, after reacting with the primary antibodies for 1 h or overnight 170 at room temperature, the sections were incubated with HRP-conjugated swine anti-rabbit immunoglobulin antibody (P0399; Dako) or rabbit anti-rat immunoglobulin antibody (P0450; Dako), diluted 1:50, for 30 min at room temperature. The reaction sites were visualized by treating the sections with H2O2 and 3,3xx'-diaminobenzidine tetrahydrochloride (26). Finally, the sections were counterstained with methyl green and mounted. For all specimens, negative 175 controls were prepared using normal IgG instead of the primary antibody.
IMMUNOFLUORESCENCE STAINING
Io K, et al., Page 9 The following antibodies were used for immunofluorescence staining: (1) (reverse) (31) . 220 
STATISTICAL ANALYSIS
Data were expressed as mean ± standard error mean (SEM). Differences among groups were examined for statistical significance by using repeated measures analysis of variance (Bonferroni/Dunn test). A p value of < 0.05 denoted statistically significant difference.
225
RESULTS
SAHA PREVENTED THE PERITONEAL FIBROSIS
Morphological changes were assessed using Masson's trichrome staining (Figure 1 ). In the normal mice, the peritoneal tissue comprised a peritoneal mesothelial monolayer and an exiguity of connective tissues under the mesothelial layer ( Figure 1A) . In the control group, 230 the peritoneal tissues were almost normal and without thickening of the submesothelial zone ( Figure 1B) . On the other hand, the peritoneal samples from the mice in the CG group had a marked thickening of the submesothelial compact zone and a heavy infiltration of various cells at day 21 ( Figure 1C ). However, subcutaneous injection of SAHA prevented the progression of submesothelial thickening and reduced the number of cells in the CG + SAHA 235 group ( Figure 1D ). A significant difference between the CG group and the CG + SAHA group was seen in the area of the submesothelial compact zone (p < 0.05, Figure 1E ). The thickening of the peritoneum was not affected following repeated injections of SAHA compared with that of the control group (data not shown).
For the analysis of collagen deposition, we conducted the immunohistochemistry for type III 240 collagen at day 21. As shown in Figure 2 , in the control group, type III collagen expression in the submesothelial compact zone was marginal and equivalent to that of normal mice ( Figure   2A ). In the CG group, type III collagen was diffusely expressed in the submesothelial compact zone, whereas this expression was clearly decreased in the CG + SAHA group ( Figure 2B, 2C) . When we examined the signal for type III collagen quantitatively, the 245 expression of type III collagen was higher in the CG group than in the control group, but was significantly lower in the CG + SAHA group than in the CG group ( Figure 2E ). Io K, et al., Page 12 The expression of FSP-1, which is a marker of fibroblasts, was examined by immunohistochemistry. A few FSP-1-positive cells were in the peritoneum of the control group (data not shown). In the CG group, the number of FSP-1-positive cells increased 250 markedly compared to that in the control group, and the treatment of SAHA inhibited these expressions significantly ( Figure 3A -3D ). Furthermore, we examined the expression of xxaSMA, which is a marker of myofibroblasts, by immunohistochemistry. In the control group, a few xxaSMA-positive cells were found in the peritoneum (data not shown). The CG group showed a significant increase of xxaSMA-positive cells, and in the CG + SAHA group, 255 the number of xxaSMA-positive cells was markedly decreased ( Figure 3E -3H ).
SAHA SUPPRESSED TRANSFORMING GROWTH FACTOR (TGF)-XXB SIGNALING
We examined TGF-xxb signaling by performing immunohistochemistry for phosphorylated-Smad2/3, which is known as a mediator of TGF-xxb signaling in regulation of the fibrotic response ( Figure 4 ). In the control group, very few phosphorylated-Smad2/3-positive cells 260 were observed in the peritoneum (data not shown). Treatment with CG significantly increased the number of phosphorylated-Smad2/3-positive cells in the thickened submesothelial compact zone compared with that in the control group ( Figure 4A ).
Compared with that in the CG group, the number of positive cells was markedly reduced in the CG + SAHA group (Figure 4B, 4D) . 265 Next, we investigated the expression of TGF-xxb-dependent pro-fibrotic genes in the peritoneum tissue using real-time RT-PCR ( Figure 4E -4G ). In the CG group, COLIxxa1, fibronectin and CTGF mRNA levels were higher than the control group. On the other hand, COLIxxa1, fibronectin and CTGF mRNA levels showed a tendency to be lower in the SAHA group. 270 
SAHA INCREASED THE LEVEL OF HISTONE ACETYLATION
Using immunofluorescence technique, we examined the level of H3K9 acetylation, which is representative of histone acetylation, in the cells of the submesothelial compact zone ( Figure   5 ). H3K9 acetylation was low in the cells of the peritoneum of the control group ( Figure 5A) . 275 In the CG group, moderate H3K9 acetylation was observed in the thickened submesothelial compact zone. In contrast, in the CG + SAHA group, the level of H3K9 acetylation tended to be higher than that in the CG group (Figure 5B, 5C ).
SAHA INCREASED THE EXPRESSION OF BMP-7
Next, we focused on BMP-7 as an inhibitory factor for fibrosis that is upregulated by the 280 administration of HDACi (21) . As shown in Figure 6 , we examined the ratio of BMP-7positive cells to all submesothelial cells in the submesothelial compact zone. In the control group, a few BMP-7-positive cells were detected in the peritoneum ( Figure 6A ). Although in the CG group some BMP-7-positive cells were in the submesothelial compact zone, the ratio of BMP-7-positive cells was significantly increased in the CG + SAHA group compared 285 with that in the CG group ( Figure 6B -6E) . The BMP-7 mRNA level in the CG + SAHA group was significantly higher than levels in the CG group ( Figure 6F ).
SAHA SUPPRESSED INFLAMMATION AND ANGIOGENESIS
To examine anti-inflammatory and anti-angiogenic effects by SAHA in peritoneal tissues, we used immunohistochemistry for F4/80 and CD31, which are markers of macrophages or 290 dendritic cells, and vessels respectively ( Figure 7A -7H ). In the peritoneum of the CG + SAHA group, the numbers of both F4/80-positive cells and CD31-positive vessels were less than those of the CG group. We identified anti-inflammatory and anti-angiogenic effects of SAHA in models of peritoneal fibrosis. Io K, et al., Page 14 DISCUSSION 295 Our results indicated that SAHA effectively ameliorated peritoneal fibrosis. In addition, we confirmed that SAHA, as an HDAC inhibitor, promoted histone acetylation in the submesothelial compact zone of the peritoneum. Our study supports the existing data and reveals the beneficial effects of HDACi on fibrotic diseases. Previous studies described the effects of HDACi in various animal models, including heart failure (9), unilateral ureteral 300 obstruction (8) , and diabetic nephropathy (32) . However, to our knowledge, this is the first study to investigate whether HDACi have inhibitory effects on peritoneal fibrosis.
Because increased levels of histone acetylation are usually associated with transcriptional activation (20), we speculated that the promotion of histone acetylation could be an effective strategy for the suppression of peritoneal fibrosis. In the present study, we focused on the 305 expression of BMP-7 among fibrosis inhibitory factors. It is an endogenous protein that belongs to the TGF-xxb superfamily and is known to prevent the development of fibrosis in various organs (33) (34) (35) . BMP-7 has been suggested to suppress fibrosis by inhibiting TGF-xxb1 synthesis (36) and by controlling TGF-xxb signaling via blocking the nuclear translocation of phosphorylated Smad2/3 (37) . In fact, the association between BMP-7 and 310 histone acetylation has been already shown (22). Marumo, et al. reported that marked induction of BMP-7 and the increase of strongly positive cells for acetylated histone were observed simultaneously in the proximal tubular cells during the recovery phase following renal ischemic reperfusion in mice (22). We also confirmed that the number of BMP-7positive cells increased in the submesothelial compact zone in the CG + SAHA group 315 compared with that in the CG group, and our results suggested that BMP-7 is involved in the suppression of peritoneal fibrosis, where it inhibits TGF-xxb signaling. Although we do not yet understand the difference observed between the levels of BMP-7 mRNA and protein level in the control group, this difference could have been caused by post-transcriptional regulation of protein synthesis, including mRNA stability and translational efficiency (38) . 320 In this study, the peritoneal samples from mice in the CG group had a marked thickening of the submesothelial compact zone and a heavy infiltration of various cells at day 21. The results of immunohistochemistry for F4/80, FSP-1 and xxaSMA suggested that a heavy infiltration of various cells in the peritoneum were mainly macrophages or dendritic cells, and myofibroblasts. The SAHA group had fewer inflammatory cells and myofibroblasts, in 325 addition to displaying an inhibition of angiogenesis. Therefore, SAHA might have ameliorated peritoneal fibrosis by not only increasing the expression of BMP-7 but also inhibiting inflammation or angiogenesis.
Our study has some limitations for clinical application. First, there are some differences between CG-induced peritoneal fibrosis and human peritoneal fibrosis. CG models induce a 330 chemical irritant but the etiology of human EPS is more complicated (4). However, most of the histological changes in CG models are similar to peritoneal fibrosis in humansinjection of CG results in progression of fibrosis and thickening of the peritoneum similar to human peritoneal fibrosis. Second, we started the administration of SAHA and CG simultaneously; the effect of SAHA as a therapeutic intervention subsequent to starting CG is 335 unknown. Therefore, we anticipate further investigation into the therapeutic effect of SAHA.
Third, the dosage of SAHA used in our study was almost 3 times that used clinically in the treatment of human cutaneous T cell lymphoma. There were no side effects such as liver or kidney dysfunction and the increase in mortality between the CG + SAHA group and the control group in our investigation. The effective and safe dose of SAHA for mice may be 340 different from that used for humans. Further studies are needed to clarify whether SAHA can Io K, et al., Page 16 be used to reduce peritoneal fibrosis in PD patients and to examine the suitable dose of SAHA for humans.
In conclusion, we have shown for the first time that SAHA inhibits the progression of peritoneal fibrosis in a mouse CG-induced peritoneal fibrosis model. Our result might be 345 consistent with our hypothesis that SAHA inhibits the expression of fibrosis-associated factors via induction of BMP-7. Thus, SAHA represents a novel potential candidate for the treatment of peritoneal fibrosis. 
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